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Objectives: The Ross procedure has emerged as an attractive option for aortic valve
replacement in children and young adults. Our objective was to review our experi-
ence with the Ross procedure in young patients with congenital aortic valve disease.
We also sought for evidence of growth in the autograft.
Methods: From January 1990 to July 2000, 260 patients underwent the Ross proce-
dure for various aortic valve diseases. There were 136 patients less than 18 years of
age. Fifty-three (38%) of these patients had congenital aortic valve disease. Ages
ranged from 3 months to 18 years (mean, 8 ± 5 years; median, 9 years). Ten patients
were less than 2 years of age. Pure aortic stenosis was present in 18 patients, mixed
stenosis and regurgitation in 32, and pure aortic regurgitation in 3. The aortic valve
was bicuspid in 29 patients. Twenty-nine patients had previous procedures, mostly
balloon dilation of the aortic valve (n = 8) or surgical aortic valvotomy (n = 12).
Results: In all patients immediate results demonstrated a normally functioning
neoaortic valve with not more than trivial aortic valve regurgitation. In the patients
with stenosis, all levels of obstruction were relieved, and the gradient across the left
ventricular outflow tract was completely abolished. Hospital mortality was 3 (5.6%)
of 53 (overall Ross mortality was 34 of 260 [1.5%]). The patients were followed up
for a mean of 4 years and up to 10 years. One patient died late of a noncardiac
cause. Actuarial survival at 10 years was 94% ± 2%, and freedom from all events
was 93% ± 5%. Only 1 patient needed autograft replacement for endocarditis.
Intervention related to right ventricle–pulmonary artery conduit was required in 3
patients: balloon dilatation in 2, and reoperation in 1. At last follow-up, all patients
but one were classified as being in New York Heart Association functional class I or
II with normal or near-normal autograft valve function. Serial measurement of the
left ventricular outflow tract and aortic root showed that as patients grew, the size
of the outflow tract increased. When indexed to body surface area, this increase cor-
related with the patients’ expected somatic growth.
Conclusions: The Ross procedure for congenital aortic valve disease in children and
young adults offers excellent hemodynamics, with the added advantage of real
potential for growth. It should be considered the treatment of choice in this age
group.
Management of aortic valve disease in children and youngadults is somewhat controversial. Aortic valve replacement,whether with a mechanical prosthesis or a bioprosthesis, canbe unsatisfactory. Mechanical valves require long-term anti-coagulation, with its known potential for complications.There is always a threat of thromboembolism and bleeding.1
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Young adults’ participation in some sports activity might
have to be restricted. Management of anticoagulation dur-
ing pregnancy can be a real problem. There is always the
risk of valve thrombosis,2,3 and warfarin is known to have
teratogenic effects on the fetus.4 Bioprosthetic valves have
a very high rate of early calcification and failure in this age
group.5 Allografts also have a high failure rate when
implanted in the very young.6 Because of continued growth
of these patients, there is always a need for multiple valve
replacements. Aortic valve replacement with the autologous
pulmonary valve (the Ross procedure) eliminates almost all
these problems. There is no risk of thromboembolism, and
there is a definite potential for growth.7 The autologous
valve allows a growing child to have a normal lifestyle.
There is a more than 80% likelihood of freedom from reop-
eration at 10 years and a 97% probability of freedom from
any sort of right ventricular outflow tract (RVOT) compli-
cations or reoperation at 20 years.8
Because of all of this, we adopted the policy of using the
pulmonary autograft for aortic valve replacement in the
very young whenever feasible.
Methods
From January 1990 to July 2000, 260 patients had aortic valve
replacement with the autologous pulmonary valve (the Ross pro-
cedure). There were 136 patients less than 18 years of age. Fifty-
three (38%) of these had congenital aortic valve disease, and these
patients constitute the study group. Ages ranged from 3 months to
18 years, with a mean of 8 ± 5 years (median, 9 years). Ten
patients were less than 2 years of age. Pure aortic stenosis was
present in 18 patients, 32 had both aortic stenosis and regurgita-
tion, and 3 had pure aortic regurgitation. There were 29 (55%)
male patients and 24 (45%) female patients. Twenty-nine patients
had previous procedures (Table 1). The aortic valve was bicuspid
in 29 patients. Forty-one patients were classified as being in New
York Heart Association functional class I or II, 8 patients were in
class III, and 4 patients were in class IV. Fifty-one patients were in
sinus rhythm, 1 was in atrial fibrillation, and 1 had a pacemaker
from a previous operation.
The autograft was implanted as a full root with coronary trans-
fer using conventional cardiopulmonary bypass with double venous
cannulation. Temperature was kept between 28°C and 32°C.
Cardioplegic solution was delivered in both an antegrade and ret-
rograde fashion. The neoaortic anulus was not reinforced in these
patients, so as not to limit growth. In patients with left ventricular
outflow tract (LVOT) obstruction, a modified Ross-Konno tech-
nique was used. Part of the septum was actually cored out to com-
pletely open up the LVOT without creating a ventricular septal
defect. In those patients the fibrous anulus of the aortic valve was
often divided, and the cut was partially taken down to the septum.
In all patients this resulted in complete relief of the obstruction, and
the often larger pulmonary autograft could be accommodated
nicely in the aortic position. In none of the patients was the pul-
monary autograft significantly smaller than the aortic root.
However, on the basis of our overall Ross experience, up to a 3- to
4-mm discrepancy in size can be accommodated. The RVOT was
reconstructed with either an aortic or pulmonary homograft. These
were either cryopreserved or fresh-antibiotic preserved. In 1
patient, however, no homografts were available, and a valved tube
constructed of glutaraldehyde-treated autologous pericardium was
used. The median diameter was 22 mm (range, 19-25 mm). Patients
less than 14 years of age were given cyclosporine A (INN:
ciclosporin) orally at a dosage of 1 mg · kg–1 · d–1.
The immediate postoperative result was assessed in all patients
in the operating room by means of transesophageal echocardiog-
raphy. Patients were evaluated clinically and by means of detailed
echocardiography 6 weeks after the operation, at 6 months, and
yearly thereafter.
Patient survival analysis and actuarial estimates of freedom
from postoperative events were accomplished by means of the Cox
life table method.
Results
The mean cardiopulmonary bypass time was 109 ± 36 min-
utes (range, 52-243 minutes), and the mean aortic cross-
clamp time was 79.5 ± 24 minutes (range, 45-164 minutes).
Immediate echocardiographic evaluation in the operating
room demonstrated good results in all patients with not
more than trivial aortic valve regurgitation. All levels of
TABLE 1. Interventions before the Ross procedure
Procedure No. of patients
AV balloon dilation 8
AV surgical valvotomy 12
± AV repair + coarctation 1
+ VSD + LVOTO + coarctation 1
Resection of SAM 5
Other congenital disorder 4
PDA 1
VSD 1
VSD + coarctation 1
VSD + aortic interruption 1
AV, Aortic valve; SAM, subaortic membrane; VSD, ventricular septal
defect; LVOTO, LVOT obstruction; PDA, patent ductus arteriosus.
TABLE 2. Status of the neoaortic valve function after the
Ross procedure in the 49 survivors
AR AS
None 18 49
Trivial 12 0
Mild 16 0
Moderate 3 0
Severe 0 0
None of the patients has aortic stenosis (AS), whereas some aortic regur-
gitation (AR) is noted.
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obstruction were completely relieved, with the gradients
being completely abolished. There were 3 (5.6%) in-hospi-
tal deaths. All 3 patients had severe aortic valve stenosis and
LVOT obstruction associated with severe left ventricular
hypertrophy. Their ages were 2, 9, and 13 years. Their
deaths were related to myocardial dysfunction, probably
caused by inadequate myocardial preservation, ischemia, or
both. There was no significant morbidity, with only 1
patient needing reoperation for bleeding. Another patient
needed implantation of a permanent pacemaker.
The patients were followed up for up to 10 years, with a
mean follow-up of 4 years. One patient died late of a non-
cardiac cause. Actuarial survival at 10 years was 94% ± 2%,
and freedom from all events was 93% ± 5%. One patient
needed reoperation for autograft failure related to endo-
carditis 1 year after undergoing the Ross procedure.
Intervention related to right ventricle–pulmonary artery
conduit was required in 3 patients: balloon dilation with
moderate success in 2 patients and reoperation in 1 patient.
The reoperation was for the patient who had the valved glu-
taraldehyde-treated autologous pericardial conduit to recon-
struct the RVOT. It was replaced with a pulmonary
homograft. The aortic valve was functioning normally.
At last follow-up, all patients but 1 were classified in
New York Heart Association functional class I or II with
normal or near-normal autograft function (Table 2). One of
the patients with moderate aortic regurgitation also had
impaired left ventricular function, requiring medical ther-
apy with angiotensin-converting enzyme inhibitors,
digoxin, and diuretics. All the other patients had preserved
left ventricular function.
The homografts in the pulmonary position demonstrated
gradients in 14 patients. In 9 of these patients, the gradients
were of less than 35 mm Hg and were well tolerated, with
no associated right ventricular dilation or dysfunction. Five
(9%) patients had gradients of greater than 50 mm Hg.
Three of them needed intervention. Most homografts also
had some degree of pulmonary regurgitation, which in some
existed without stenosis (Table 3).
Serial echocardiographic measurements of the LVOT
and aortic root diameter demonstrated that as the patients
grew, the size of the LVOT increased. When indexed to
body surface area, the increase correlated with the patients’
expected somatic growth (Figure 1).
Discussion
The surgical management of aortic valve disease in the
young has been confined to prosthetic replacement in most
centers. Mechanical valves need lifelong anticoagulation,
with its known risk of thromboembolism and bleeding.
Noncompliance with medical treatment and pregnancy fur-
ther accentuate this problem. The use of bioprostheses is
discouraged because of early failure and degeneration.
Allografts, although with relatively longer durability than
stented bioprostheses, are still not advisable in children.
Their limited availability also restricts widespread use.
Aortic valve repair techniques have been applied but to a
limited extent. Currently, there is a growing interest in these
techniques, but they are associated with some failures and
the need for reoperation.9
Figure 1. LVOT size after Ross procedure for congenital aortic
valve disease. BSA, Body surface area.
Figure 2. LVOT size comparing rheumatic versus congenital aortic
valve disease after Ross procedure.
TABLE 3. Degree of pulmonary valve regurgitation after
homograft replacement after the Ross procedure in the 49
survivors
Pulmonary regurgitation No. of patients
None/trivial 20
Mild 16
Moderate 9
Severe 4
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Aortic valve replacement with the autologous pulmonary
valve offers the advantages of a viable,10 nonstented tissue
valve with growth potential.7,11 It does not require anticoag-
ulation, and with its proven long-term outcome,11,12 the indi-
cations for its use are becoming broader, especially in young
patients. At the end of 1999, close to 4000 patients have been
enrolled into the international Ross registry (personal com-
munication, Ross Procedure International Registry, St
Patrick Hospital, Missoula, Mont). Faced with a predomi-
nantly young and rheumatic patient population in whom
anticoagulation control is extremely difficult, we adopted
the procedure in our institution in January 1990. Since then
and until the end of July 2000, 260 patients underwent the
Ross procedure, with an overall mortality of 1.5%. Seventy
percent of our patients have rheumatic disease. Initially,
there was a significant need for reoperation in this group of
patients because of progression of aortic regurgitation in the
autograft. Rheumatic valvulitis was documented in some
explanted autograft valves at reoperation, indicating that the
transplanted pulmonary valve can be sensitive to rheumatic
fever. Our concern about the use of the Ross operation in
patients with rheumatic disease was reported.13,14 We also
found that associated concomitant severe mitral valve regur-
gitation was a strong predictor of autograft failure. The pres-
ence of dilated aortic root preoperatively was another risk
factor predictive of failure. We now do not offer the Ross
procedure for rheumatic aortic valve regurgitation if the root
is more than 28 mm in diameter.
In our effort to reduce the reoperation rate, we found that
patients with predominant aortic stenosis had a much lesser
incidence of reoperation than those with pure aortic regur-
gitation, who tend to have larger aortic roots. We therefore
decided to look at our subgroup of patients with congenital
aortic valve disease and determine whether they differed
from those with a rheumatic cause.
Patients with congenital aortic valve disease were
younger (mean age, 8 ± 5 years vs 18 ± 9 years in those with
rheumatic disease). They had more stenotic lesions and
smaller LVOTs (Figure 2).
As our experience indicates, the pulmonary autograft
replacement of the aortic valve seems to be the ideal solu-
tion in children and young adults. The operation can be
accomplished with a relatively low operative risk. The root
replacement technique can correct almost all pathologic
lesions associated with the aortic valve and the LVOT. A
severely obstructed LVOT can be dealt with adequately by
means of modified Ross-Konno procedure in which the
LVOT is enlarged in the area of the septum without actually
creating a ventricular septal defect, and the aortic valve is
replaced with the pulmonary autograft. However, it is the
opinion of many others that if the patient’s own aortic valve
is of acceptable quality, then one should attempt to do a
repair, preserving the valve whenever possible.15
Late valve function has been excellent, and the only pri-
mary autograft failure was related to endocarditis. All other
patients have normal or near-normal autograft valve func-
tion (Table 2), with no evidence of deterioration up to 10
years of follow-up. The Ross operation appears to have a
significant advantage in survival and quality of life in chil-
dren requiring valve replacement not only as a first opera-
tion but also after a prior aortic valve procedure.16
Problems with the homograft used in reconstruction of the
RVOT are not significant, although up to about 20% of
patients tend to have gradients. In this series 9 (16%) of 53
patients had gradients of less than 35 mm Hg. An additional
5 (9%) patients had gradients of more than 50 mm Hg. Three
of these patients required intervention: 2 balloon dilations
and 1 operation. The balloon dilation resulted in only modest
reduction in the gradients. Balloon dilation in such patients
generally is not successful in relieving the gradients alto-
gether because the gradients result from diffuse narrowing of
the homograft involving the homograft valve anulus, the pul-
monary artery, and also the distal suture line and often are
associated with calcification and thickening in the valve
leaflets. If, however, the stenosis was only caused by narrow-
ing of the distal suture line, balloon dilation may be more
successful. The diffuse nature of the narrowing is thought to
represent a consequence of an immune-mediated response to
the homograft.17,18 Because of this, we empirically give our
young patients who receive homografts cyclosporine at 1 mg
· kg–1 · d–1 orally. This dosage is quite small and will not
cause any significant adverse effects and yet may slow down
the rate of homograft degeneration. It is also worth mention-
ing that the risk for development of homograft stenosis is
greatest during the first 1 to 3 years postoperatively.
Subsequently, it appears that the gradients stabilize in most of
the patients. Our policy therefore is to observe these patients
unless there is evidence of right ventricular strain on the elec-
trocardiogram or right ventricular dilation or dysfunction on
echocardiography. If there is uncertainty, we evaluate the
patient during exercise. If the exercise tolerance is affected,
then intervention is indicated. With this, our reoperation rate
on the right side for the whole Ross group is only 2%. In this
subgroup the only patient who needed reoperation on the
right side had a valved conduit constructed of glutaralde-
hyde-treated autologous pericardium. One reason that homo-
grafts do well in RVOT reconstruction after the Ross
procedure is the fact that the homograft is actually lying in its
anatomic position with most favorable hemodynamics,
unlike the situation with most right-sided reconstructions for
congenital heart disease, where the homograft lies on top of
the ventricle, making hemodynamics less than ideal.
Additionally, patients undergoing the Ross procedure have a
relatively normal pulmonary vascular bed compared with that
of patients with congenital heart disease, who often have
abnormalities in their distal pulmonary bed.
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One of the great advantages of the Ross operation is the
real potential for growth. There is no doubt that serial mea-
surements of the LVOT and aortic root demonstrate pro-
gressive increase in size. When the measurements are
indexed, the change in size appears proportional to somatic
growth. However, the argument is always whether this is
growth or dilation.19 To us, this probably represents growth
rather than dilation. Solymar and colleagues,11 in their
study of 8 infants with critical aortic stenosis who under-
went the Ross operation early in life, concluded that the
pulmonary autograft in the aortic position does increase in
size and that the pattern of this increase is suggestive of pas-
sive dilation in the early postoperative period, followed by
normal active growth.
In conclusion, the Ross procedure for congenital aortic
valve disease in children and young adults offers excellent
hemodynamics, with the added advantage of real potential
for growth. Reoperations on the reconstructed RVOT are
infrequent and are much less demanding and life-threaten-
ing. The Ross procedure therefore should be considered the
treatment of choice in this age group.
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Discussion
Dr Ronald C. Elkins (Oklahoma City, Okla). I would like to
congratulate Dr Al-Halees and his group for an excellent clinical
series of Ross operations in patients with congenital heart operations.
My first point is that I was struck by the differences in his
patient population compared with that in most reported series. The
male/female ratio was almost equal in this series, whereas in most
of the series reported in the United States, a male/female ratio of
at least 3:1 is reported. Could you suggest a reason for this?
The operative results were excellent, and the early postopera-
tive echocardiographic results were likewise excellent, with no
evidence of obstruction and only trivial autograft valve regurgita-
tion. In this series of 49 patients with midterm follow-up (mean of
4 years), 16 patients now have mild and 3 have moderate autograft
regurgitation. This is of some concern, especially with the length
of follow-up.
Although you have demonstrated a mean value of the autograft
anulus of 22 mm and a left ventricular outflow index that appears
to have decreased over time, I would be more comfortable with
your data on autograft growth if you had presented this informa-
tion as the individual’s z values of the anulus on the basis of the
body surface area rather than a mean value, which in the wide
range of ages that you have probably does not reflect the true
growth in some of these patients. Certainly, if you have a 22-mm
anulus as your mean value, there are some patients who have an
anulus significantly greater than one would anticipate for that
body surface area. A 26-mm anulus means you have some patients
with a body surface area of 2.6 mm2 for this to be normal. This
would suggest that perhaps dilation has occurred in some patients.
Did you have any patients who had a dilated aortic anulus at the
time of the operation, and did you alter the management of these
patients?
How did you select the size of your allograft valves? Although
you have suggested a very low incidence of reoperation or RVOT
complication, that certainly has not been our experience or the
experience of other centers looking at these patients. In your data
you report a 28% incidence of the allografts having some obstruc-
tion and 22% having moderate or severe pulmonary insufficiency.
What do you think the real incidence of homograft valve dysfunc-
tion is going to be in this group of patients as they are followed up
for 10 years?
I agree with your conclusions but believe that we have much to
learn about this operation. There are many areas where continued
study will allow us to change and alter our operative techniques,
so that our patients may have better results.
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Dr Al-Halees. Thank you, Dr Elkins, for your remarks and
questions. Your contributions for the Ross procedure have been
very well known and outstanding.
In regard to the male/female ratio, I think there are some
regional differences that could exist, and I believe this is probably
because of that fact. For example, in our area, in general, LVOT
obstructions are much rarer than the right-sided obstructions.
Therefore, we see a lot of right-sided obstructions in our popula-
tion, a higher incidence of tetralogy of Fallot, for example, than
would be seen in the Western literature. I believe that there are
some geographic and maybe racial differences between our popu-
lation and the population in the West.
In terms of relating the growth to the body surface area in the
way you suggested, I think this is what we will probably do in the
group, particularly if we have a longer follow-up. What you have
suggested is a more accurate measure of defining the growth ver-
sus dilatation. There was a publication from a group in Sweden
that looked at 8 infants who underwent the Ross procedure at 2
weeks of age, and the suggestion from that article is that there is
an initial dilatation followed by a real growth of the autograft.
In terms of the allograft, the mean size for our patients was 22
mm, and we really do not have any specific formula to choose the
size. We just go ahead and use the largest size possible for that
patient. It also depends on the availability of the homograft in our
storage. In general, homografts are not freely available for us as
they are here, and we depend entirely on importing those from
other sources. In the one patient who had the allograft explanted,
a pericardial tube was reconstructed because, at the time, we did
not have any homografts available.
Our incidence of reoperation for the allograft failure is lower
because of our higher tolerance for pulmonary regurgitation and
stenosis. As I mentioned, we noticed, in our group of patients, that
the greatest hazard for development of the stenosis is really early
on, maybe the first 1, 2, or 3 years; afterward it seems that the
process becomes much slower, and these patients can be managed
well medically without reoperation.
Of course, for the whole group, a longer follow-up is required.
We will keep monitoring them, and ideally in a few years we will
have a longer follow-up. My own belief is that patients with
rheumatic valve disease who have aortic stenosis as a manifesta-
tion of their aortic valve disease, or stenosis and regurgitation with
the stenosis being the predominant lesion, will not have the same
problems as patients with aortic regurgitation. I think that those
patients with stenosis as the lesion will probably have stable func-
tion of the autograft. That is only a prediction. Only time can tell.
Dr Abdulla Ashmeg (Jeddah, Saudi Arabia). I have 2 ques-
tions for Dr Al-Halees.
First, sometimes we see a string sign on the right side, the
homograft, that develops fairly early after the Ross operation.
What is the cause of this severe diffuse stenosis of the homograft,
and is it related?
My second question is related to one of your slides, where you
showed that the progress of the obstruction of the right side slows
down. I cannot understand that in a growing patient, such as in
children. As they grow, the homograft is not going to grow. I
expect stenosis to become more severe with time rather than to
progress more slowly.
Dr Al-Halees. Thank you. I think some of those patients
indeed have diffuse obstruction in the allograft that starts at the
valve anulus and involves the valve leaflets, the pulmonary wall,
and the distal anastomosis. Although there is no definite evidence
in the literature, it is believed that there is some sort of an immune
response that could be the reason behind this type of diffuse
obstruction. Actually, when this happens, the balloon dilatation of
this stenosis will not result in good relief of the obstruction.
Maybe for the same reason it can be used to explain why the
process can slow down later on. I think when all the immune reac-
tion is kind of dealt with in the first couple of years, then the
process slows down, and there is no further deterioration in the
obstruction. Of course, the condition of some patients will con-
tinue to deteriorate, with higher and higher gradients, but that is
the smaller number of patients and not the whole group.
